NHGRI logo

Genome Technology Program

The Genome Technology Program is refining current technologies to increase efficiency and decrease cost while maintaining or improving data quality, and developing completely novel approaches to achieve orders-of-magnitude improvement.

Overview

The Genome Technology program at NHGRI supports research to develop new methods, technologies and instruments that enable rapid, low-cost determination of nucleic acid sequence and genotyping along with epigenetic, functional and synthetic genomics experiments. The development of completely novel approaches and achieving orders-of-magnitude improvements in genomic technologies are foundational efforts of the program. The refinement of current technologies to increase efficiency and decrease cost while maintaining or improving data quality and the integration of process steps is key to achieving these goals.

The program also supports and coordinates technology transfer from developers to users, and promotes collaborative, multidisciplinary programs that closely integrate research projects in academic and industrial laboratories.

Resources

Genome Technology Program Bibliography: Publications and Patents

NHGRI launched an ambitious program in 2004 to reduce the cost of full mammalian genome sequencing initially by 100-fold and subsequently by an additional 100-fold, aiming ultimately at about $1,000. Below, listed by Principal Investigator, are citations and links to many of the articles and patents resulting from this program and closely related research.

Genome Technology Program Publications and Patents

Genome Technology Program Related Information

Genome Technology Program Reports

Genome Technology Program Policies

Active Funding Opportunities

RFAs

  • RFA-HG-20-014: Novel Synthetic Nucleic Acid Technology Development (R01 Clinical Trial not allowed)
  • RFA-HG-20-015: Novel Synthetic Nucleic Acid Technology Development (R21) (Clinical Trial not allowed)
  • RFA-HG-20-016: Novel Synthetic Nucleic Acid Technology Development (R43/R44) (Clinical Trial Not Allowed)
  • RFA-HG-21-001: Technology Development for Single-Molecule Protein Sequencing and Single-Cell Proteome Analysis (R01 Clinical Trial not allowed)
  • RFA-HG-21-002: Technology Development for Single-Molecule Protein Sequencing (R21 Clinical Trial not allowed)
  • RFA-HG-21-006: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R01 Clinical Trial not Allowed)
  • RFA-HG-21-007: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 Clinical Trial not Allowed)
  • RFA-HG-21-008: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44 Clinical Trial not Allowed)
     

PAR

  • PAR-21-247: Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial Not Allowed)
     

Notice of Special Interest (NOSI)

  • NOT-HG-21-018: Advancing Genomic Technology Development for Research and Clinical Application

Inactive Funding Opportunities

RFAs

  • RFA-HG-20-019: NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed)
  • RFA-HG-18-001: Novel Nucleic Acid Sequencing Technology Development (R01 Clinical Trial Not Allowed)
  • RFA-HG-18-002: Novel Nucleic Acid Sequencing Technology Development (R21 Clinical Trial Not Allowed)
  • RFA-HG-18-003: Novel Nucleic Acid Sequencing Technology Development (R43/R44 Clinical Trial Not Allowed)
     

PARs

  • PAR-18-777: Novel Genomic Technology Development (R01 Clinical Trial Not Allowed)
  • PAR-18-778: Novel Genomic Technology Development (R21 Clinical Trial Not Allowed)
  • PAR-18-779: Novel Genomic Technology Development (R43/R44 Clinical Trial Not Allowed)

Advanced Sequencing Technology Awards

In 2004, NHGRI initiated a coordinated effort to support the development of technologies to dramatically reduce the cost of DNA sequencing, a move aimed at broadening the applications of genomic information in medical research and health care.

Program Staff

Mike Smith
Mike Smith, Ph.D.
  • Program Director Genome Technology Program
  • Division of Genome Sciences
Stephanie Morris
Stephanie A. Morris, Ph.D.
  • Program Director
  • Division of Genome Sciences

Last updated: July 23, 2021